Onco-Innovations Engages in University of Alberta's Innovation Awards

Onco-Innovations Limited, a Vancouver-based company, participated in the 2025 Innovation Awards hosted by the University of Alberta on November 21, 2025. This event acknowledges groundbreaking research that brings university discoveries into practical applications. This marks the first occasion technology licensees like Onco were involved, indicating the university's increasing emphasis on industry cooperation.

Onco-Innovations partnered with the University of Alberta in 2024 through an exclusive license agreement for PNKP Inhibitor Technology, aimed at enhancing the effectiveness of cancer treatments. Based on 15 years of research, this technology has achieved nine patents, focusing on DNA repair mechanisms in cancer cells. It aims to boost chemotherapy and radiation efficiency by delaying DNA repair.

The company's collaboration continues with preclinical studies and development, aiming for forthcoming clinical evaluations. Furthermore, the board approved the issuance of 60,000 Restricted Share Units to certain directors, aligning with its equity incentive strategy.